NewAmsterdam Pharma Company N.V. (NAMS)Healthcare | Biotechnology | Naarden, Netherlands | NasdaqGM
34.68 USD
+1.48
(4.458%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 34.68 Short-term: ★★☆☆☆ | Long-term: ☆☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 18, 2026, 11:35 p.m. EDT
NAMS is a catastrophic long-term hold (0) due to a revenue collapse (-99.8% growth), negative cash flow, and -2060% operating margins, making any current valuation mathematically unsound based on current fundamentals. While the stock has run up 15% in the last two weeks and bears strong 'Strong Buy' analyst consensus, the underlying business is hemorrhaging capital. The recent analyst upgrade and positive positioning appear to be driven by 'event risk' (the EU launch of the cholesterol drug in Q2) rather than sustainable profitability. Investors should strictly limit exposure to the binary outcome of the upcoming clinical data, as the fundamental trend is severely negative. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.055778 |
| AutoETS | 0.055778 |
| MSTL | 0.055944 |
| AutoTheta | 0.065654 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 80% |
| H-stat | 0.86 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.212 |
| Excess Kurtosis | -1.28 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 0.03 |
| Revenue per Share | 0.19 |
| Market Cap | 3,987,347,712 |
| Forward P/E | -25.18 |
| Beta | 0.13 |
| Website | https://www.newamsterdampharma.com |
As of April 18, 2026, 11:35 p.m. EDT: Options data reveals a mixed sentiment with distinct expiration clusters. There is heavy in-the-money put positioning at the $35 strike for the July 2026 expiration (496 volume/496 open interest), indicating a strong bet on downside at or near the weekly low. Conversely, long-term calls show significant volume accumulation on the $45 strike for Jan 2028, coupled with a $2.9K call pool in July 2026, suggesting some players are positioned for a potential rebound to historical highs if a data catalyst occurs. However, the near-term ATM IV (0.74 for May calls) was elevated but the OI is low compared to deep OTM calls further out, suggesting current market pricing focuses on volatility rather than a specific binary event in the next month.
| Attribute | Value |
|---|---|
| 52 Week Change | 1.1328413 |
| Address1 | Gooimeer 2-35 |
| All Time High | 42.0 |
| All Time Low | 5.633 |
| Ask | 34.81 |
| Ask Size | 1 |
| Average Analyst Rating | 1.3 - Strong Buy |
| Average Daily Volume10 Day | 862,630 |
| Average Daily Volume3 Month | 796,536 |
| Average Volume | 796,536 |
| Average Volume10Days | 862,630 |
| Beta | 0.131 |
| Bid | 34.57 |
| Bid Size | 1 |
| Book Value | 5.974 |
| City | Naarden |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | Netherlands |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 34.68 |
| Current Ratio | 7.876 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 34.955 |
| Day Low | 33.57 |
| Debt To Equity | 0.03 |
| Display Name | NewAmsterdam Pharma Company |
| Earnings Timestamp | 1,771,421,400 |
| Earnings Timestamp End | 1,778,157,000 |
| Earnings Timestamp Start | 1,778,157,000 |
| Ebitda | -225,463,008 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -14.864 |
| Enterprise To Revenue | 148.927 |
| Enterprise Value | 3,351,308,544 |
| Eps Current Year | -1.68615 |
| Eps Forward | -1.3771763 |
| Eps Trailing Twelve Months | -1.72 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 32.7499 |
| Fifty Day Average Change | 1.9300995 |
| Fifty Day Average Change Percent | 0.058934513 |
| Fifty Two Week Change Percent | 113.284134 |
| Fifty Two Week High | 42.0 |
| Fifty Two Week High Change | -7.3199997 |
| Fifty Two Week High Change Percent | -0.17428571 |
| Fifty Two Week Low | 15.82 |
| Fifty Two Week Low Change | 18.86 |
| Fifty Two Week Low Change Percent | 1.1921619 |
| Fifty Two Week Range | 15.82 - 42.0 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,612,881,000,000 |
| Float Shares | 71,466,423 |
| Forward Eps | -1.3771763 |
| Forward P E | -25.181961 |
| Free Cashflow | -112,909,872 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 100 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 1.0 |
| Gross Profits | 22,503,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.00972 |
| Held Percent Institutions | 1.06275 |
| Implied Shares Outstanding | 114,975,422 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,022-11-23 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands. |
| Long Name | NewAmsterdam Pharma Company N.V. |
| Market | us_market |
| Market Cap | 3,987,347,712 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_685404834 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -203,819,008 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 3,987,347,634 |
| Number Of Analyst Opinions | 14 |
| Open | 34.19 |
| Operating Cashflow | -147,783,008 |
| Operating Margins | -2,061.875 |
| Payout Ratio | 0.0 |
| Phone | 31 35 206 2971 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 34.68 |
| Post Market Time | 1,776,458,837 |
| Previous Close | 33.2 |
| Price Eps Current Year | -20.567566 |
| Price Hint | 2 |
| Price To Book | 5.8051558 |
| Price To Sales Trailing12 Months | 177.19183 |
| Profit Margins | 0.0 |
| Quick Ratio | 7.686 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.33333 |
| Region | US |
| Regular Market Change | 1.48 |
| Regular Market Change Percent | 4.45783 |
| Regular Market Day High | 34.955 |
| Regular Market Day Low | 33.57 |
| Regular Market Day Range | 33.57 - 34.955 |
| Regular Market Open | 34.19 |
| Regular Market Previous Close | 33.2 |
| Regular Market Price | 34.68 |
| Regular Market Time | 1,776,456,000 |
| Regular Market Volume | 636,731 |
| Return On Assets | -0.17266001 |
| Return On Equity | -0.2829 |
| Revenue Growth | -0.998 |
| Revenue Per Share | 0.19 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 114,975,422 |
| Shares Percent Shares Out | 0.07 |
| Shares Short | 8,047,048 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 7,658,931 |
| Short Name | NewAmsterdam Pharma Company N.V |
| Short Percent Of Float | 0.0832 |
| Short Ratio | 8.6 |
| Source Interval | 15 |
| Symbol | NAMS |
| Target High Price | 61.453434 |
| Target Low Price | 37.977425 |
| Target Mean Price | 49.774223 |
| Target Median Price | 48.491886 |
| Total Cash | 636,241,024 |
| Total Cash Per Share | 5.534 |
| Total Debt | 202,000 |
| Total Revenue | 22,503,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.72 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 31.211075 |
| Two Hundred Day Average Change | 3.4689255 |
| Two Hundred Day Average Change Percent | 0.11114406 |
| Type Disp | Equity |
| Volume | 636,731 |
| Website | https://www.newamsterdampharma.com |
| Zip | 1,411 DC |